Fostamatinib

TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Side effects, and when to stop

The following clinically important adverse reactions, that can become serious are described elsewhere in the labeling:

Hypertension [ see Warnings and Precautions ]
Hepatotoxicity [ see Warnings and Precautions ]
Diarrhea [ see Warnings and Precautions ]
Neutropenia [ see Warnings and Precautions ]

Who should not take it

None.

Storing it

Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Do not remove desiccants.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Fostamatinib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/fostamatinib
APA 7th: sofidex. (2026, August 2). Fostamatinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/fostamatinib
AMA 11th: Fostamatinib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/fostamatinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.